By: Tanya Lewis writing for Scientific American
Pancreatic cancer is one of the deadliest forms of cancer, with very few effective treatments. But messenger RNA (mRNA) vaccines—famous for their ability to prevent COVID—are starting to show some promise against the lethal cancer. In a recent early-stage trial, half of pancreatic cancer patients who received a personalized mRNA cancer vaccine after surgery did not have a recurrence of the tumor a year and a half later. The trial, which was described in a study published on Wednesday in Nature, was small—with just 16 patients—and it will need to be replicated in larger studies.
To read more, click here.
